<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801463</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0801</org_study_id>
    <nct_id>NCT00801463</nct_id>
  </id_info>
  <brief_title>Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis</brief_title>
  <official_title>Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of prednisone and tripterygium wilfordii
      in treated Focal Segmental Glomerulosclerosis (FSGS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary FSGS is a leading cause of end stage renal disease in adults, with complete loss of
      kidney function in 50% of patients over 10 years. Steroids, which are currently used to treat
      the disease, are effective in part of patients. Over the past decade, a number of studies
      have reported therapeutic efficacy for treatment with high-dose and over 6mo prednisone in
      patients with FSGS. These studies show that the total effective rates were only around 50%.
      But this therapy had taken some side effects of prednisone. Except these studies, in recent
      studies suggest that Tripterygium Wilfordii may be effective for passive Heymann nephritis,
      podocyte injury in nephrosis rats induced y puromycin aminonucleoside, and so on. FSGS is a
      podocytepathy. There was no-data of Prednisone and Tripterygium Wilfordii treatment of
      Chinese adult patients with idiopathic FSGS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy and safety of TW in the treatment of FSGS</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Proteinuria</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Large pred</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone 60mg/d*8 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>small pred</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pred 30mg/d*8wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tripterygium wilfordii (TW)</intervention_name>
    <description>Pre 30mg/d +TW 120 mg/d, po for 12 weeks</description>
    <arm_group_label>Large pred</arm_group_label>
    <arm_group_label>small pred</arm_group_label>
    <other_name>tripterygium wilfordii</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60 years at onset of signs or symptoms of FSGS

          -  Urine protein ≥ 3.5 g/24 h

          -  Estimated glomerular filtration rate (GFR) ≥ 40 ml/min/1.73 m2, serum
             creatinine&lt;2.5mg/dl

          -  Biopsy confirmed as idiopathic FSGS (including all subtypes)

          -  Willingness to follow the clinical trial protocol, including medications, and baseline
             and follow-up visits and procedures

        Exclusion Criteria:

          -  Secondary FSGS

          -  Prior therapy with sirolimus, Cyclosporine, MMF, azathioprin, cytoxan, chlorambucil,
             levamisole, methotrexate, or nitrogen mustard in the last 90 days

          -  Active/serious infection

          -  Malignancy

          -  Previously diagnosed as diabetes mellitus type 1 or 2, or abnormal carbohydrate
             tolerance

          -  Peripheral white blood cells &lt; 3000/ul

          -  Clinical evidence of cirrhosis or chronic active liver diseases

          -  History of significant gastrointestinal disorder

          -  Allergy to study medications, and Inability to consent/assent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-hong Liu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>May 17, 2011</last_update_submitted>
  <last_update_submitted_qc>May 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name_title>
    <organization>Research Institute of Nephrology, Jinling Hospital</organization>
  </responsible_party>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Tripterygium Wilfordii</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

